Keyphrases
Hospitalized Patients
100%
Placebo-controlled
100%
Hyperimmune Serum
100%
Patients with COVID-19
100%
Hyperimmune Immunoglobulin
100%
Intravenous Immunoglobulin (IVIg)
100%
Randomized Phase III Trial
100%
Placebo
50%
COVID-19
50%
Safety Outcomes
40%
Neutralizing Antibodies
20%
Modified Intention-to-treat
20%
Remdesivir
20%
End Organ Failure
20%
Placebo Groups
10%
Randomized Placebo-controlled Trial
10%
Adverse Events
10%
Standard of Care
10%
Pharmacist
10%
Randomized Clinical Trial
10%
Subgroup Analysis
10%
Treatment Effect
10%
Organ Failure
10%
Symptom Duration
10%
Favorable Outcome
10%
U.S. National Institutes of Health
10%
Pharmacy
10%
Intention-to-treat Analysis
10%
Efficacy Outcomes
10%
Group Allocation
10%
Antibody-negative
10%
Clinical Care
10%
Patient-specific Therapy
10%
Urn Design
10%
Death Events
10%
Baseline Factors
10%
Passive Immunity
10%
Anti-spike
10%
Extra-pulmonary Complications
10%
Trial Participants
10%
Infusion Reaction
10%
Ordinal Endpoint
10%
Serious Infection
10%
Equivalent Volume
10%
Ordinal Outcome
10%
Medicine and Dentistry
Placebo
100%
Immunoglobulin
100%
COVID-19
100%
Hyperimmune Globulin
100%
Infusion
40%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
Infection
20%
Symptom
20%
Intention-to-Treat Analysis
20%
Neutralizing Antibody
20%
Remdesivir
20%
Randomized Clinical Trial
10%
Sodium Chloride
10%
Adverse Event
10%
Subgroup Analysis
10%
Treatment Effect
10%
Immunotherapy
10%
Nursing and Health Professions
Placebo
100%
Immunoglobulin
100%
Hyperimmune Globulin
100%
Infusion
40%
Severe Acute Respiratory Syndrome
30%
Symptom
20%
Infection
20%
Intention to Treat Analysis
20%
Remdesivir
20%
Neutralizing Antibody
20%
Sodium Chloride
10%
Randomization
10%
Adverse Event
10%
Health Care Quality
10%
National Health Organization
10%
Spike
10%
Immunotherapy
10%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Immunoglobulin
100%
Hyperimmune Globulin
100%
SARS Coronavirus
30%
Infection
20%
Symptom
20%
Neutralizing Antibody
20%
Remdesivir
20%
Sodium Chloride
10%
Adverse Event
10%
Randomized Clinical Trial
10%
Immunotherapy
10%